Print this page
-
NRG-BN012, A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases
Protocol: 142302Principal Investigator:
- Nicholas DeNunzio MD, PhD (Rutgers Cancer Institute of New Jersey)
Applicable Disease Sites: Brain and Nervous System -
NRG-GU012: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Study (SAMURAI)
Protocol: 082305Principal Investigator:
- Lara Hathout MD (Rutgers University)
Applicable Disease Sites: Kidney -
A Phase 3 Randomized, Open-label Study of MK-5684 Versus Alternative
Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant
Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA)
and Taxane-based Chemotherapy
Protocol: 082306Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Prostate -
A Phase 3, Randomized, Open-label Study of MK-5684 (004) Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Nextgeneration Hormonal Agent (NHA)
Protocol: 082307Principal Investigator:
- Biren Saraiya M.D (Rutgers University)
Applicable Disease Sites: Prostate -
CTEP #10512: A Phase 2 Randomized Study of the BER Inhibitor TRC102 in Combination with Standard Pemetrexed-Platinum-Radiation in Stage III Non-Squamous Non-Small Cell Lung Cancer
Protocol: 032309Principal Investigator:
- Salma Jabbour M.D. (Rutgers University)
Applicable Disease Sites: Lung -
S2206, Phase III Trial of Neoadjuvant Durvalumab (NSC 778709) plus Chemotherapy versus Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive / Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer.
Protocol: 042315Principal Investigator:
- Mridula George (Rutgers University)
Applicable Disease Sites: Breast